Latest Period
Q1 2026
Security Snapshot
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) Institutional Ownership
CUSIP: 15117B202
13F Institutional Holders and Ownership History from Q4 2018 to Q1 2026
Institutions Reporting
226
Shares (Excl. Options)
72,942,404
Price
$31.72
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001
- Symbol
- CLDX on Nasdaq
- Shares outstanding
- 80,000,000
- Price per share
- $33.66
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 72,942,404
- Total reported value
- $2,312,966,589
- % of total 13F portfolios
- 0.01%
- Share change
- -482,759
- Value change
- -$8,937,083
- Number of holders
- 226
- Price from insider filings
- $33.66
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 is tracked under CUSIP 15117B202.
- 226 institutions reported positions in Q1 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 183 to 226 between Q4 2025 and Q1 2026.
- Reported value moved from $1,992,599,502 to $2,312,966,589.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 226 institutions filings for Q1 2026.
Security key
15117B202
Latest holder period
Q1 2026
13F holders
226
13D/G owners
10
CIK / CUSIP context first
Open Q1 2026 holders
CLDX full holder history
Celldex Therapeutics, Inc. SEC filings
Celldex Therapeutics, Inc. company facts
Celldex Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 15117B202:
Significant Owners of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 12% | +10% | $219,442,153 | +$18,600,852 | 8,079,608 | +9.3% | Wellington Management Group LLP | 31 Dec 2025 |
| BlackRock, Inc. | 7.3% | -12% | $100,867,802 | -$13,842,621 | 4,819,293 | -12% | BlackRock, Inc. | 31 Mar 2025 |
| FMR LLC | 5.6% | -24% | $117,195,241 | -$34,655,461 | 3,749,048 | -23% | FMR LLC | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $109,332,337 | 3,446,795 | Vanguard Capital Management | 31 Mar 2026 | |||
| Commodore Capital LP | 4.6% | -8% | $78,343,026 | -$8,321,474 | 3,028,335 | -9.6% | Commodore Capital LP | 30 Sep 2025 |
| STATE STREET CORP | 4.2% | -18% | $87,658,292 | -$18,554,217 | 2,804,168 | -17% | STATE STREET CORPORATION | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.6% | -36% | $61,640,475 | -$30,382,633 | 2,382,701 | -33% | T. Rowe Price Associates, Inc. | 30 Sep 2025 |
| Point72 Asset Management, L.P. | 2.6% | -59% | $43,255,582 | -$66,568,658 | 1,758,357 | -61% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC | 2% | $30,459,938 | 1,356,186 | Eventide Asset Management, LLC | 30 Jun 2025 | |||
| Bellevue Group AG | 1.5% | -78% | $37,512,000 | -$75,576,333 | 1,200,000 | -67% | Bellevue Group AG | 31 Mar 2026 |
As of 31 Mar 2026, 226 institutional investors reported holding 72,942,404 shares of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX). This represents 91% of the company’s total 80,000,000 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) together control 70% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 11% | 8,560,476 | +6% | 0.05% | $271,538,300 |
| Kynam Capital Management, LP | 7.3% | 5,840,567 | -1.7% | 12% | $185,262,785 |
| BlackRock, Inc. | 6.7% | 5,369,885 | -1.5% | 0% | $170,332,752 |
| FMR LLC | 4.7% | 3,749,048 | -24% | 0.01% | $118,919,804 |
| Point72 Asset Management, L.P. | 4% | 3,229,939 | +84% | 0.18% | $102,453,665 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 2,960,895 | 0% | 0% | $93,919,589 |
| STATE STREET CORP | 3.5% | 2,804,168 | -17% | 0% | $88,948,209 |
| Commodore Capital LP | 3.4% | 2,696,616 | +5.1% | 4.9% | $85,536,660 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.6% | 2,086,332 | +2.3% | 0.01% | $66,179,000 |
| Eversept Partners, LP | 2.2% | 1,788,016 | +25% | 3.7% | $56,715,868 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,688,074 | +3.7% | 0% | $53,556,480 |
| BRAIDWELL LP | 1.7% | 1,356,082 | -27% | 1.4% | $43,014,921 |
| Deep Track Capital, LP | 1.6% | 1,283,979 | -32% | 0.84% | $40,727,814 |
| MILLENNIUM MANAGEMENT LLC | 1.6% | 1,253,532 | +3.4% | 0.03% | $39,762,035 |
| Vestal Point Capital, LP | 1.5% | 1,224,165 | +5.1% | 1.1% | $38,830,514 |
| Bellevue Group AG | 1.5% | 1,200,000 | -67% | 0.91% | $38,064,000 |
| NOVO HOLDINGS A/S | 1.5% | 1,200,000 | 0% | 3.1% | $38,064,000 |
| DIMENSIONAL FUND ADVISORS LP | 1.3% | 1,059,534 | +63% | 0.01% | $33,595,626 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.3% | 1,037,000 | -37% | 0.54% | $32,893,640 |
| Fisher Asset Management, LLC | 1.3% | 1,013,648 | +8.2% | 0.01% | $32,152,913 |
| GOLDMAN SACHS GROUP INC | 1.2% | 988,416 | -7.5% | 0% | $31,352,555 |
| Pictet Asset Management Holding SA | 1.2% | 923,696 | -4.6% | 0.03% | $29,299,637 |
| Elmind Capital, LP | 1.1% | 865,000 | 0% | 7.8% | $27,437,800 |
| AMERICAN CENTURY COMPANIES INC | 1.1% | 856,310 | +0.13% | 0.01% | $27,162,211 |
| BANK OF AMERICA CORP /DE/ | 0.89% | 708,647 | +71% | 0% | $22,478,282 |
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 72,942,404 | $2,312,966,589 | -$8,937,083 | $31.72 | 226 |
| 2025 Q4 | 73,373,402 | $1,992,599,502 | +$45,987,039 | $27.16 | 183 |
| 2025 Q3 | 70,729,708 | $1,829,814,017 | -$41,022,042 | $25.87 | 180 |
| 2025 Q2 | 72,686,329 | $1,479,214,886 | -$18,971,957 | $20.35 | 178 |
| 2025 Q1 | 73,628,376 | $1,336,550,222 | -$25,518,368 | $18.15 | 170 |
| 2024 Q4 | 73,686,767 | $1,861,792,917 | -$10,935,353 | $25.27 | 172 |
| 2024 Q3 | 71,809,989 | $2,440,639,326 | +$62,002,971 | $33.99 | 174 |
| 2024 Q2 | 69,594,154 | $2,575,716,559 | +$1,332,092 | $37.01 | 181 |
| 2024 Q1 | 69,311,318 | $2,908,781,828 | +$362,625,073 | $41.97 | 196 |
| 2023 Q4 | 60,989,057 | $2,418,831,729 | +$410,573,840 | $39.66 | 162 |
| 2023 Q3 | 50,572,705 | $1,391,763,899 | +$5,531,719 | $27.52 | 140 |
| 2023 Q2 | 50,188,683 | $1,702,972,802 | +$19,493,416 | $33.93 | 148 |
| 2023 Q1 | 49,503,692 | $1,779,547,358 | +$24,122,749 | $35.98 | 158 |
| 2022 Q4 | 48,677,430 | $2,169,609,749 | -$9,316,822 | $44.57 | 163 |
| 2022 Q3 | 49,338,461 | $1,386,923,833 | +$32,333,656 | $28.11 | 146 |
| 2022 Q2 | 48,218,738 | $1,300,004,065 | -$45,672,202 | $26.96 | 146 |
| 2022 Q1 | 49,602,527 | $1,689,417,077 | +$106,143,717 | $34.06 | 157 |
| 2021 Q4 | 46,338,765 | $1,790,195,856 | +$97,400,922 | $38.64 | 170 |
| 2021 Q3 | 43,227,306 | $2,333,703,184 | +$430,296,249 | $53.99 | 156 |
| 2021 Q2 | 35,559,554 | $1,189,106,240 | +$60,325,552 | $33.44 | 127 |
| 2021 Q1 | 34,503,199 | $709,497,850 | -$40,255,166 | $20.60 | 109 |
| 2020 Q4 | 36,816,222 | $645,045,236 | +$72,177,637 | $17.52 | 120 |
| 2020 Q3 | 32,156,087 | $476,873,776 | +$67,764,471 | $14.83 | 82 |
| 2020 Q2 | 27,786,246 | $361,216,517 | +$310,785,532 | $13.00 | 63 |
| 2020 Q1 | 3,949,694 | $6,557,892 | +$7,227 | $1.66 | 32 |
| 2019 Q4 | 3,904,189 | $8,706,543 | +$447,617 | $2.23 | 34 |
| 2019 Q3 | 3,708,146 | $7,895,004 | +$465,004 | $2.13 | 40 |
| 2019 Q2 | 3,466,005 | $9,286,115 | +$2,108,302 | $2.68 | 39 |
| 2019 Q1 | 2,603,854 | $12,809,043 | +$12,313,782 | $4.92 | 39 |
| 2018 Q4 | 100,357 | $20,000 | +$20,000 | $0.20 | 1 |